Asterias Biotherapeutics (NYSEMKT: AST), a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.
AST develops therapeutic products in the areas of neurology and oncology.
Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. AST also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase.
Asterias Biotherapeutics was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
- June 2, 2018 - 7:11am | Out and About, Out and About, Earnings, Earnings Q1
- March 10, 2018 - 9:22am | Earnings, Earnings Q4
- March 4, 2018 - 11:11am | Analysis, Out and About
- November 3, 2017 - 1:08pm | Earnings, Earnings Q3
- June 13, 2017 - 9:00am | Research Notes
- May 5, 2017 - 8:59am | Earnings, Earnings Q1
- March 10, 2017 - 12:00am | Earnings, Earnings Q4
- February 7, 2017 - 12:42pm | Research Notes
- January 24, 2017 - 1:07pm | Research Notes
- November 2, 2016 - 8:46pm | Earnings, Earnings Q3
- August 31, 2016 - 8:52am | Research Notes
- August 4, 2016 - 10:50pm | Earnings, Earnings Q2
- July 12, 2016 - 9:45am | Research Notes
- May 24, 2016 - 7:32am | Research Notes, Henry'omics
- May 10, 2016 - 8:54am | Henry'omics, Financings
- February 29, 2016 - 2:51pm | Henry'omics, BOD & C-Suite Updates
- February 24, 2016 - 8:31am | Research Notes, Henry'omics
- November 16, 2015 - 10:34am | Earnings Q3
- November 2, 2015 - 7:44am | BOD & C-Suite Updates
- September 9, 2015 - 10:22am | Research Notes, Regulatory